Literature DB >> 10381112

Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods.

P C Fuchs1, A L Barry, S D Brown.   

Abstract

One hundred percent of 1097 Escherichia coli and 97.5% of 157 Enterococcus faecalis isolates from outpatient urine specimens at ten North American medical centres were susceptible to fosfomycin tromethamine. The Etest MICs correlated well with those of agar dilution. Disc diffusion zone diameters correlated well with MICs and supported the previously proposed zone diameter breakpoints for fosfomycin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381112     DOI: 10.1093/jac/43.1.137

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Antibiotic Selection for Urinary Tract Infection: New Microbiologic Considerations.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

2.  In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Authors:  M de Cueto; L López; J R Hernández; C Morillo; A Pascual
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Fosfomycin: an old, new friend?

Authors:  M Popovic; D Steinort; S Pillai; C Joukhadar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-14       Impact factor: 3.267

4.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.

Authors:  Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Treatment of resistant enterococcal urinary tract infections.

Authors:  Subramanian Swaminathan; George J Alangaden
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

7.  Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci.

Authors:  James A Karlowsky; Melanie R Baxter; Alyssa R Golden; Heather J Adam; Andrew Walkty; Philippe R S Lagacé-Wiens; George G Zhanel
Journal:  J Clin Microbiol       Date:  2021-09-08       Impact factor: 5.948

8.  Susceptibility of Clinical Isolates of Escherichia coli to Fosfomycin as Measured by Four In Vitro Testing Methods.

Authors:  James A Karlowsky; Philippe R S Lagacé-Wiens; Nancy M Laing; Melanie R Baxter; Heather J Adam; George G Zhanel
Journal:  J Clin Microbiol       Date:  2020-09-22       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.